Guardian Partners’s Sarepta Therapeutics SRPT Stock Holding History

Guardian Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$377	Buy	+21	New	+$397	﹤0.01%	387

Other funds holding SRPT

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Guardian Partners's SRPT Position: Q2 2026 in Review

Guardian Partners opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 21 shares worth $377. The stake represents ﹤0.01% of the portfolio and ranks #387 among its holdings.

63 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Guardian Partners held 21 shares of Sarepta Therapeutics worth $377 as of Q2 2026.
Sarepta Therapeutics was a new Guardian Partners position in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Guardian Partners's portfolio in Q2 2026, its #387 holding.
63 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Guardian Partners's 13F filing for Q2 2026, filed 29 Jul 2026.